Scholars@Duke
Katherine Barnett Peters

Katherine Barnett Peters

Professor of Neurosurgery
Neurosurgery, Neuro-Oncology
katherine.peters@duke.edu
047 Baker House, Trent Drive, BOX_3624, Durham, NC 27710
Office hours Per Request  

Scholarly Works - Conferences

TIP-25. Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results

Conference Neuro-Oncology · November 11, 2025 AbstractBACKGROUNDLerapolturev is a modified, non-pathogenic version of the Sabinâ„¢ type 1 poliovirus vaccine that infects myelo ... Full text Cite

INNV-39. Response to next interventions after treatment with off-label ivosidenib in patients with mutant IDH low grade glioma

Conference Neuro-Oncology · November 11, 2025 AbstractThe introduction of mutant IDH inhibitors (mIDHi) has transformed the treatment landscape for patients with low-grade gliomas (LGG). However, optimal strategies for tumor control following progres ... Full text Cite

QOL-07. Vitamin B6 supplementation for levetiracetam-associated mood changes in patients with brain tumor-related epilepsy

Conference Neuro-Oncology · November 11, 2025 AbstractSeizures are a common and debilitating complication of primary brain tumors. Nearly 75% of low-grade and 25% of high-grade glioma patients experience seizures. Levetiracetam (LEV) is frequently us ... Full text Cite

BIOM-79. TARGETING FGFR ALTERATIONS IN GLIOMAS: A SINGLE-INSTITUTION CASE SERIES

Conference Neuro-Oncology · November 11, 2025 AbstractBACKGROUNDFibroblast growth factor receptor (FGFR) alterations are a potentially actionable target in various cancers, ... Full text Cite

IMG-89. Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

Conference Neuro-Oncology · November 11, 2025 AbstractWhile Response Assessment in Neuro-oncology (RANO) criteria remain the standard for brain tumor evaluation, 3D volumetric measurements may provide more accurate tumor assessments. We compared 2D R ... Full text Cite

INNV-41. Real-World utilization of vorasidenib in patients with IDH-mutant glioma: early insights on patient characteristics, disease history, and prior treatment patterns

Conference Neuro-Oncology · November 11, 2025 AbstractBACKGROUNDVorasidenib, a dual inhibitor of mutant IDH1/2 enzymes, was approved in mid-2024 as a targeted therapy for pa ... Full text Cite

CTNI-53. PATIENTS WITH ISOCITRATE DEHYDROGENASE-MUTANT GLIOMA TREATED WITH VORASIDENIB: UPDATED DATA FROM THE VORASIDENIB EXPANDED ACCESS PROGRAM

Conference Neuro-Oncology · November 11, 2025 AbstractBACKGROUNDVorasidenib (VOR) is an inhibitor of mutant isocitrate dehydrogenase 1/2 (mIDH1/2). We previously reported ou ... Full text Cite

TMIC-78. Aquaporin-4 loss in astrocytes drives glioblastoma-associated cerebral edema and alters the tumor immune microenvironment

Conference Neuro-Oncology · November 11, 2025 AbstractGlioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with a dismal 5-year survival rate of ~6.5%. Vasogenic cerebral edema is a severe complication that occurs in th ... Full text Cite

IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial

Conference Neuro-Oncology · November 11, 2025 AbstractTGR shows emerging utility as a quantitative measure for assessing treatment efficacy in glioma. We evaluated three distinct TGR models using volumetric data from patients with mIDH1/2 diffuse gli ... Full text Cite

EPCO-62. ASSESSMENT OF AGE IN THE CLINICAL RISK STRATIFICATION OF PATIENTS WITH IDH-MUTANT GLIOMAS

Conference Neuro-Oncology · November 11, 2025 AbstractBACKGROUNDIsocitrate dehydrogenase mutant (IDHm) low-grade gliomas have a slow growing phase, but eventually become agg ... Full text Cite

INNV-37. Real-world observation rates and treatment patterns in IDH-mutated glioma: implications for targeted therapy use

Conference Neuro-Oncology · November 11, 2025 AbstractINTRODUCTIONThe approval of vorasidenib marks a paradigm shift in the management of IDH-mutated (mIDH) gliomas. This st ... Full text Cite

TMOD-41. Evaluating Response to Mutant IDH Inhibition in Lower Grade Gliomas Using Artificial Intelligence-Based Brain Tumor Volumetrics

Conference Neuro-Oncology · November 11, 2025 AbstractOrally available inhibitors of mutant IDH (mIDHis) have emerged as a promising new therapy for patients with lower grade mIDH gliomas, yet the therapeutic response is challenging to assess objecti ... Full text Cite

JS05.6.A EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB

Conference Neuro-Oncology · October 3, 2025 AbstractBACKGROUNDGrade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas are slowly progressive, malignant, incurable brain ... Full text Cite

OS09.4.A EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL

Conference Neuro-Oncology · October 3, 2025 AbstractBACKGROUNDIn the Phase 3 INDIGO trial (NCT04164901), vorasidenib, an oral, brain-penetrant, dual inhibitor of mutated isocitra ... Full text Cite

Assessment of age in the clinical risk stratification of patients with IDH-mutant gliomas.

Conference Journal of Clinical Oncology · June 2025 2058Background: Prognosis for mutant isocitrate dehydrogenase (mIDH) gliomas is influenced by tumor type, size, neurologic de ... Full text Cite

CTNI-66. IDH-MUTANT GLIOMA PATIENTS TREATED WITH VORASIDENIB: ONGOING DATA FROM THE VORASIDENIB EXPANDED ACCESS PROGRAM

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDVorasidenib (VOR) is an oral, brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1/2 (mIDH1/2) demons ... Full text Cite

CTIM-01. OUTCOMES AND IMMUNE RESPONSES AFTER PEPTIDE VACCINATION TARGETING HUMAN CYTOMEGALOVIRUS ANTIGEN PP65 IN CHILDREN AND YOUNG ADULTS WITH RECURRENT HIGH-GRADE GLIOMA AND MEDULLOBLASTOMA: RESULTS OF A PHASE 1 TRIAL

Conference Neuro-Oncology · November 11, 2024 AbstractINTRODUCTIONThe human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblast ... Full text Cite

INNV-07. IVOSIDENIB AND BEVACIZUMAB IN HEAVILY PRETREATED PATIENTS WITH IDH1 MUTANT GLIOMAS

Conference Neuro-Oncology · November 11, 2024 AbstractIsocitrate dehydrogenase 1 (IDH1) inhibitors are transforming the treatment of patients with non-enhancing IDH1 mutant gliomas that have only undergone surgical resection. Questions remain on the uti ... Full text Cite

LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Conference Neuro-Oncology · November 11, 2024 AbstractGBM AGILE(NCT03970447) is a phase 2/3 Bayesian adaptive registration platform trial testing multiple therapies against a common control. P ... Full text Cite

INNV-31. THE USE OF IVOSIDENIB IN PATIENTS WITH ENHANCING IDH1 MUTANT GLIOMAS

Conference Neuro-Oncology · November 11, 2024 AbstractIvosidenib offers a novel targeted therapy for non-enhancing IDH1 mutated gliomas following initial resection. Potential effects of IDH inhibitors on enhancing disease in clinical settings are not we ... Full text Cite

INNV-37. REAL-WORLD OUTCOMES AMONG HIGH GRADE IDH1-MUTANT GLIOMA PATIENTS TREATED WITH AN IDH INHIBITOR

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDIsocitrate dehydrogenase (IDH) inhibitors are transforming the treatment of patients with non-enhancing grade 2 IDH- ... Full text Cite

NIMG-77. MRI PHENOMENON OF PUNCTATE ENHANCING LESIONS IN PATIENTS TREATED WITH IDH INHIBITORS

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDMagnetic Resonance Imaging (MRI) response assessment is essential in isocitrate dehydrogenase (IDH)-mutant gliomas a ... Full text Cite

CTNI-64. TRIAL IN PROGRESS: DIET2TREAT -- A RANDOMIZED MULTICENTER PHASE 2 TRIAL OF A KETOGENIC DIET VS STANDARD DIETARY GUIDANCE IN COMBINATION WITH STANDARD-OF-CARE TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDMany glioblastoma (GBM) patients inquire about the potential therapeutic benefits of a high fat / low carbohydrate k ... Full text Cite

CTNI-53. A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH ADULT-TYPE DIFFUSE GLIOMA WITH AN IDH1/2 MUTATION (INDIGO): UPDATED EFFICACY RESULTS

Conference Neuro-Oncology · November 11, 2024 AbstractINTRODUCTIONThe Phase 3 INDIGO study (NCT04164901) evaluated vorasidenib, an oral, brain-penetrant, dual inhibitor of mutated ... Full text Cite

CTNI-30. A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PROSPECTIVE, PLACEBO CONTROLLED STUDY OF NANOâ‚‚TM COMBINED WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA: RESTORE

Conference Neuro-Oncology · November 11, 2024 AbstractINTRODUCTIONGlioblastoma (GBM) commonly has extensive hypoxic regions, possibly due to thrombosis from tumor-produced pro-coag ... Full text Cite

CTNI-57. REAL-WORLD EVIDENCE OF THE FREQUENCY OF POST-SURGICAL INITIAL OBSERVATION IN PATIENTS WITH IDH-MUTANT GLIOMA

Conference Neuro-Oncology · November 11, 2024 AbstractBACKGROUNDAfter initial resection of IDH-mutant gliomas, initial observation is an option for low-risk patients, to postpone p ... Full text Cite

P18.37.B REPEATED CONVECTION-ENHANCED DELIVERY (CED) INFUSION OF A POLIO/RHINOVIRUS RECOMBINANT (LERAPOLTUREV; LERA) IN RECURRENT GLIOBLASTOMA (RGBM) PATIENTS, FOLLOWED BY CERVICAL PERILYMPHATIC INJECTIONS OF LERA (LERA-CPLI)

Conference Neuro-Oncology · October 17, 2024 AbstractBACKGROUNDPhase 1 and 2 clinical trials of a single intratumoral injection of LERA (previously PVSRIPO) via CED into enhancing ... Full text Cite

Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma

Conference Journal of Clinical Oncology · January 1, 2024 Background: The human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblastoma but not in adjacent brain. The primary objective of this first-in-human phase I trial (NCT03299309) was to assess the safety a ... Full text Cite

KS02.6.A INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE III STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION

Conference Neuro-Oncology · September 8, 2023 AbstractBACKGROUNDGrade 2 gliomas are slowly progressive, malignant brain tumours with a poor long-term prognosis. Current treatments ... Full text Cite

Investigation of leptomeningeal disease in high grade glioma and characterization of molecular alterations.

Conference Journal of Clinical Oncology · June 1, 2023 2070 Background: Leptomeningeal disease (LMD) is a challenging complication of high grade glioma (HGG) and questions remain regarding risk factors, molecular associations, and optimal treatment. Here we report updated results on ... Full text Cite

NCOG-43. A RETROSPECTIVE ANALYSIS OF THE IMPACT OF THE COVID-19 INFECTION ON NEURO-ONCOLOGY CARE AND PATIENT OUTCOMES: A TWO-SITE STUDY

Conference NEURO-ONCOLOGY · November 14, 2022 BACKGROUND COVID-19 radically changed neuro-oncology care. In this retrospective study, we examine the impact of COVID-19 infection on neuro-oncological care and clinical outcomes in two geographically separate populations. METHODS Descriptive statistics ... Full text Link to item Cite

CTNI-49. EARLY SIGNAL OF ACTIVITY FROM A PHASE 2 STUDY OF ST101, A FIRST-IN-CLASS PEPTIDE ANTAGONIST OF CCAAT/ENHANCER-BINDING PROTEIN Î’ (C/EBPÎ’), IN RECURRENT GLIOBLASTOMA (GBM)

Conference Neuro-Oncology · November 14, 2022 AbstractBACKGROUNDC/EBPβ is a transcription factor that is active during embryofetal development but held in an inactive state in most ... Full text Cite

Functional neurological disorders in primary brain tumor patients

Conference Advancing Care in Neuro-oncology 1 · May 3, 2022 Objective: We sought to identify the phenomenon of functional neurological disorders in our primary brain tumor patient population. Moreover, we describe factors associated with a functional neurological disorder in this cohort of patients. Background: Fun ... Full text Link to item Cite

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR wild-type and mutant-specific (EGFRvIII) monoclonal antibody (Ab) fragment and a genetically engineered form of the Pseudomonas exotoxin. When injected dir ... Full text Link to item Cite

A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma

Conference JOURNAL OF CLINICAL ONCOLOGY · 2022 Background: High-grade gliomas (HGGs) are immunologically ‘cold’ tumors. This phenomenon is partly due to reduced expression of major histocompatibility class (MHC) I on the surface of tumor cells, which prevents CD8+ cytotoxic T lymphocyte activity (CTLs) ... Full text Link to item Cite

QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE

Conference Neuro-Oncology · November 12, 2021 AbstractINTRODUCTIONThere is increasing recognition that palliative care (PC) can benefit patients with advanced cancers. However, ear ... Full text Open Access Link to item Cite

BIOM-20. TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM

Conference Neuro-Oncology · November 12, 2021 AbstractBACKGROUNDPVSRIPO is a live-attenuated recombinant rhino:poliovirus that mediates antitumor efficacy by engaging antitumor imm ... Full text Cite

EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference Neuro-Oncology · June 1, 2021 AbstractIntroductionThe cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not ... Full text Link to item Cite

LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS

Conference Neuro-Oncology · June 1, 2021 AbstractCircumscribed low-grade gliomas comprise roughly one-third of pediatric CNS tumors. Most of these tumors are caused by activating mutations in the mitogen-activated protein kinase (MAPK) pathway. Dru ... Full text Cite

Phase 2 trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.

Conference Journal of Clinical Oncology · May 20, 2021 TPS2069 Background: High-grade gliomas (WHO grade III-IV) patients experience marked morbidity and mortality. While the standard of care for newly diagnosed high-grade glioma patients is surgery followed by concurrent chemotherap ... Full text Cite

The state of neuro-oncology during the COVID-19 pandemic: A worldwide assessment

Conference Neuro Oncology Advances · January 1, 2021 Background:It remains unknown how the COVID-19 pandemic has changed neuro-oncology clinical practice, training, and research efforts. Methods:We performed an international survey of practitioners, scientists, and trainees from 21 neuro-oncology organizatio ... Full text Cite

INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB

Conference NEURO-ONCOLOGY · 2021 Isocitrate dehydrogenase 1 (IDH1) is commonly mutated in grade II-III gliomas, and the mutant enzyme leads to the production of the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG is responsible for the gliomagenesis associated with these tumors and the pro ... Full text Link to item Cite

Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.

Conference Neuro Oncol · December 18, 2020 BACKGROUND: Lower-grade gliomas (LGGs) with isocitrate dehydrogenase 1 and/or 2 (IDH1/2) mutations have long survival times, making evaluation of treatment efficacy difficult. We investigated the volumetric growth rate of IDH mutant gliomas before and afte ... Full text Link to item Cite

NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Conference Neuro-Oncology · November 9, 2020 AbstractPURPOSEThe neurologic assessment in neuro-oncology (NANO) scale was developed as a standardized metric to objectively measure ... Full text Cite

Outcomes Following Adjuvant Radiation Therapy in Elderly Patients with Glioblastoma: A Retrospective Single Institution Analysis

Conference International Journal of Radiation Oncology*Biology*Physics · September 1, 2020 2230 ... Full text Link to item Cite

CTIM-21PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL

Conference NEURO-ONCOLOGY · 2020 Abstract INTRODUCTION The cytomegalovirus (CMV) antigen, pp65, is ubiquitously expressed in malignant glioma and medulloblastoma but not in healthy brain. The objective of this Phase I trial (NCT03299309) was to assess the safety and feasibility of a novel ... Full text Link to item Cite

NCOG-23. PATTERNS OF DISTRESS IN OLDER PATIENTS WITH GLIOBLASTOMA: A FOLLOW-UP TO A SINGLE INSTITUTION CROSS-SECTIONAL STUDY OF DISTRESS IN PRIMARY BRAIN TUMOR PATIENTS

Conference NEURO-ONCOLOGY · 2020 Abstract INTRODUCTION We previously reported to SNO, high levels of psychosocial distress in adult patients with primary brain tumors (PBTs), particularly during the first 6 months following diagnosis. The purpose of this follow-up study was to identify pa ... Full text Cite

Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation

Conference Blood · November 13, 2019 Introduction: Geriatric assessment (GA) is a multidimensional evaluation of patient health and function that may detect impairments not identified as part of routine care, predict treatment-related morbidity and mortality, and inform treatment plan ... Full text Cite

PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1

Conference Neuro-Oncology · September 6, 2019 AbstractBACKGROUNDMutant isocitrate dehydrogenase (mIDH) enzymes produce the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (I ... Full text Cite

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.

Conference Journal of Clinical Oncology · May 20, 2019 e13526 Background: Recurrence of high-grade glioma (HGG) (WHO grade III-IV) is a nearly universal phenomenon and necessitates the development of new therapeutic modalities. Two possible immunotherapeutic modalities are checkpoint ... Full text Cite

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.

Conference Journal of Clinical Oncology · May 20, 2019 2060 Background: We completed a study evaluating a single intratumoral delivery of PVSRIPO in recurrent WHO grade IV MG patients (N Engl J Med. 2018 Jul 12;379(2):150-161). Some patients who originally benefitted from the infusion of PVSRIPO demonstrated ... Full text Link to item Cite

A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.

Conference Journal of Clinical Oncology · May 20, 2019 2003 Background: AG-120 (ivosidenib [IVO]) is a first-in-class oral inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1) evaluated in 66 glioma patients (pts) in an ongoing phase 1 study. AG-881 (vorasidenib [VOR]) is an oral, ... Full text Cite

Impact of glioblastoma (GBM)-related cognitive dysfunction (CD) on caregiver burden: Preliminary results from multi-site study in the U.S.

Conference Journal of Clinical Oncology · December 1, 2018 16 Background: GBM is a largely incurable, highly aggressive cancer with high incidence of CD. Caregivers face heightened stress with loved one’s limited life expectancy and additional duties. To better understand this unique gro ... Full text Cite

PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS

Conference NEURO-ONCOLOGY · November 5, 2018 QOLP-13 ... Full text Link to item Cite

Long-term outcomes of adult patients with ependymoma.

Conference Neurology · April 27, 2018 150 ... Link to item Cite

Adult pilocytic astrocytoma: clinical management and prognostic factors.

Conference Neurology · April 9, 2018 158 Objective: The purpose of this study is to analyze adult patients with pilocytic astrocytomas and to identify factors associated with recurrence and survival. Background: Pilocytic astrocytomas (WHO grade I) represent the most common central nervous s ... Link to item Cite

PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Conference Neuro-Oncology · November 1, 2017 RATE-36 INTRODUCTION Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin’s lymphoma that involves the brain, spinal cord or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~3% of all primary centr ... Full text Link to item Cite

Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).

Conference Journal of Clinical Oncology · May 20, 2017 e13533 Background: The live attenuated oral poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal c ... Full text Link to item Cite

Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma.

Conference Journal of Clinical Oncology · May 20, 2017 e13532 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin consisting of EGFR-wt and EGFRvIII monoclonal antibodies with a genetically engineered Pseudomonas exotoxin, PE-38KDEL. The primary objectiv ... Full text Link to item Cite

Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.

Conference Journal of Clinical Oncology · May 20, 2017 e21636 Background: At diagnosis, GBM patients face the immediate challenge of significant morbidity and mortality. In this population, we have shown that better exercise behavior is an independent prognostic factor for improved s ... Full text Link to item Cite

Treatment through progression with ofranogene obadenovec (VB-111), an anti-cancer viral therapy, significantly attenuates tumor growth in recurrent GBM: Individual phase 2 patient data.

Conference Journal of Clinical Oncology · May 20, 2017 2055 Background: Ofranergene obadenovec (VB-111) is a viral cancer-therapy with a dual mechanism: vascular disruption and induction of a tumor directed immune response. Prolongation of overall survival (OS) has been shown in recu ... Full text Cite

Tumor stem cell RNA-leaded dedritic cell vaccine for recurrent glioblastoma: a phase 1 trail.

Conference Neurology · April 27, 2017 Objective: To evaluate the feasibility and safety of administering brain tumor stem cell (BTSC) mRNA-loaded dendritic cells (DC) to patients with recurrent GBM. Background: BTSC CD133+ contribute to GBM propagation and are associated with chemo-radiation ... Link to item Cite

Radiogenomic analysis of lower grade glioma: A pilot multi-institutional study shows an association between quantitative image features and tumor genomics

Conference Progress in Biomedical Optics and Imaging Proceedings of SPIE · January 1, 2017 Recent studies showed that genomic analysis of lower grade gliomas can be very effective for stratification of patients into groups with different prognosis and proposed specific genomic classifications. In this study, we explore the association of one of ... Full text Cite

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).

Conference Support Care Cancer · October 2016 BACKGROUND: In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially comp ... Full text Link to item Cite

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

Conference Journal of Clinical Oncology · May 20, 2016 Background: The live attenuated oral (SABIN) serotype 1 poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal cell adhesion mo ... Full text Link to item Cite

Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).

Conference Journal of Clinical Oncology · May 20, 2016 ackground: The inherent biologic specificity of immunotherapy offers the prospect of targeting neoplastic cells more precisely. Dendritic cells (DCs) are endowed with an extraordinary ability to activate CD4+ and CD8+ T-cells, and DCs loaded with antigens ... Full text Link to item Cite

Baseline cognitive function to predict survival in patients with glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2016 Background: Overall survival of patients with glioblastoma (GBM) remains dismal with range from 12-14 months. In addition to the oncologic burden that these patients face during the disease trajectory, there are demonstrable neurologic and cognitive challe ... Full text Link to item Cite

Radiogenomics of glioblastoma: A pilot multi-institutional study to investigate a relationship between tumor shape features and tumor molecular subtype

Conference Progress in Biomedical Optics and Imaging Proceedings of SPIE · January 1, 2016 Genomic subtype has been shown to be an important predictor of therapy response for patients with glioblastomas. Unfortunately, obtaining the genomic subtype is an expensive process that is not typically included in the standard of care. It is therefore of ... Full text Cite

Predicting outcomes in glioblastoma patients using computerized analysis of tumor shape - Preliminary data

Conference Progress in Biomedical Optics and Imaging Proceedings of SPIE · January 1, 2016 Glioblastoma (GBM) is the most common primary brain tumor characterized by very poor survival. However, while some patients survive only a few months, some might live for multiple years. Accurate prognosis of survival and stratification of patients allows ... Full text Cite

Secondary cancers in long-term survivors of primary glioblastoma.

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2015 Link to item Cite

Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2015 Full text Cite

Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.

Conference Journal of Clinical Oncology · May 20, 2015 2034 ... Link to item Cite